- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07811219
RESP-FIT: A Respiratory Muscle Strength Training Intervention for COPD
10 settembre 2026 aggiornato da: Medical University of South Carolina
Individuals with chronic obstructive pulmonary disease (COPD) often experience dyspnea, low physical activity, and reduced quality of life.
RESP-FIT is a randomized controlled trial evaluating a remotely delivered respiratory muscle strength training intervention combined with mobile health tools to improve dyspnea, respiratory muscle strength, and physical activity in adults with COPD.
Panoramica dello studio
Stato
Non ancora reclutamento
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This randomized, parallel-group clinical trial will enroll adults with COPD and assign them 1:1 to either the RESP-FIT intervention or enhanced usual care.
The RESP-FIT intervention includes respiratory muscle strength training using a commercially available inspiratory muscle trainer, remote spirometry, physical activity monitoring, ecological momentary assessment of symptoms, and a mobile application for monitoring and feedback.
Primary and secondary outcomes include dyspnea, dyspnea-related kinesiophobia, respiratory muscle strength, physical activity, lung function, and quality of life, assessed over a 6-month follow-up period.
All study activities are conducted remotely.
Tipo di studio
Interventistico
Iscrizione (Stimato)
288
Fase
- Non applicabile
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Contatto studio
- Nome: Mary Chris S. Pittman, BA
- Numero di telefono: 8437923512
- Email: pittmama@musc.edu
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
No
Descrizione
Inclusion Criteria:
- Age ≥40 years
- Clinical diagnosis of COPD
- Ability to provide informed consent
- Willingness to use mobile health devices and apps
- Access to Wi-Fi and mailing address in the U.S.
Exclusion Criteria:
- Cognitive impairment preventing participation
- Active substance abuse
- Other significant respiratory disease
- Concurrent enrollment in conflicting COPD or behavioral intervention trials
- Non-English speaking
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: RESPFIT Intervention Arm
The RESP-FIT intervention group will receive the full intervention, including respiratory muscle strength training (RMST), ecological momentary assessment (EMA) symptom tracking through the mobile application, and physical activity monitoring using an activity monitor.
Participants will receive instructions from study personnel on RMST device use and will follow a simple 5x5x5 training protocol (5 breaths, 5 times a day, 5 times a week) over the intervention period.
Participants will be asked to record training sessions and symptoms using the mobile application.
The intervention period will last 6 months, with the primary endpoint occurring at 3 months following baseline.
Outcome assessments will occur at baseline and at 1, 2, 3, and 6 months.
|
The RESP-FIT intervention group will receive the full intervention, including respiratory muscle strength training (RMST), EMA symptom management through the RESP-FIT app, ecological momentary assessment (EMA) symptom tracking through the mobile application, and physical activity monitoring using the Garmin activity monitor.
Participants will receive instructions from study personnel on RMST device use and will follow a simple 5x5x5 training protocol (5 breaths, 5 times a day, 5 times a week) over the intervention period of 6 months.
Participants will also be asked to record training sessions and symptoms using the mobile application.
Participants will receive on-going support and monitoring from study personnel for the first 3 months and can use app and devices at will for the next 3 months until the 6 month assessment period when the study procedures end.
|
|
Nessun intervento: No Intervention Enhanced Usual Care Group
Participants randomized to the control group will receive enhanced usual care (eUC).
This consists of their standard COPD management provided by their healthcare providers along with the mobile app for remote spirometry and symptom tracking and physical activity monitoring using the Garmin wearable activity tracker.
Control group participants will also receive publicly available COPD educational materials (via COPD Foundation resources).
Providing an activity monitor to both groups allows the research team to account for potential effects of activity monitoring on physical activity behavior.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Maximal Inspiratory Pressure (PImax)
Lasso di tempo: Baseline to 3 Months
|
Maximal inspiratory pressure measured using the POWERbreathe Smart Adaptor digital pressure transducer connected to a mouthpiece.
|
Baseline to 3 Months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Modified Borg Dyspnea Scale Score
Lasso di tempo: Baseline to 3 Months
|
Dyspnea severity assessed using the Modified Borg Scale delivered through ecological momentary assessment (EMA) within the study mobile application.
Scores range from 0-10, with 0 indicating no breathlessness and 10 indicating maximal breathlessness.
Higher scores indicate greater dyspnea severity.
|
Baseline to 3 Months
|
|
Change in Breathlessness Beliefs Questionnaire (BBQ) Score
Lasso di tempo: Baseline to 3 Months
|
Dyspnea-related kinesiophobia assessed using the Breathlessness Beliefs Questionnaire (BBQ), a validated 11-item instrument that measures dysfunctional beliefs about breathlessness related to physical activity.
Items are rated on a 5-point scale, yielding a total score ranging from 11-55, with higher scores indicating stronger beliefs about breathlessness and greater dyspnea-related fear and activity avoidance.
|
Baseline to 3 Months
|
|
Change in Modified Medical Research Council (mMRC) Dyspnea Scale Score
Lasso di tempo: Baseline to 3 Months
|
Breathlessness measured using the Modified Medical Research Council (mMRC) Dyspnea Scale, a 5-grade scale that assesses the degree to which breathlessness limits daily physical activities.
Scores range from 0-4, with higher scores indicating breathlessness that prevents leaving the house or occurring during dressing/undressing.
Higher scores indicate worse dyspnea-related functional limitation.
|
Baseline to 3 Months
|
|
Change in PROMIS Dyspnea-Related Activity Avoidance Score
Lasso di tempo: Baseline to 3 Months
|
Activity avoidance due to breathing discomfort assessed using the PROMIS Dyspnea-Related Activity Avoidance instrument.
This is a 5 point Likert scale with 3 items measuring avoidance of activities due to shortness of breath or phsyical limitations over the past 7 days, scored from 0 (not at all) to 4 (very much), yielding total raw score range of 0-12.
Higher scores indicate greater dyspnea-related task avoidance.
|
Baseline to 3 Months
|
|
Change in St. George's Respiratory Questionnaire (SGRQ) Total Score
Lasso di tempo: Baseline to 3 Months
|
Respiratory-related quality of life assessed using the St. George's Respiratory Questionnaire (SGRQ) for COPD.
This is contains 40 items assessing three domains (symptoms, activity, and impact) and a total score ranging from 0-100, with 0 indicating no impairment and 100 indicating maximum impairment.
Higher scores indicate greater impairment in respiratory related quality of life.
|
Baseline to 3 Months
|
|
Change in Average Daily Step Count
Lasso di tempo: Baseline to 3 Months
|
Physical activity measured using a Garmin wearable activity monitor, with daily steps captured numerically in number of steps.
|
Baseline to 3 Months
|
|
Change in CAPTURE Score
Lasso di tempo: Baseline to 3 Months
|
COPD symptoms and exacerbation risk assessed using the COPD Assessment in Primary Care to Identify Undiagnosed Respiratory Disease and Exacerbation Risk (CAPTURE) questionnaire.
This is a 5 item instrument assessing respiratory symptoms, risk exposures, recent acute respiratory illnesses with a total score range of 0-6, with higher scores indicating greater likelihood of clinically significant COPD and exacerbation risk.
|
Baseline to 3 Months
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Qualitative Measures
Lasso di tempo: 3 months
|
Semi-structured interviews assessing intervention accessibility, usability, symptom monitoring, dyspnea-related activity avoidance, disease self-management, and overall participant experiences with RESP-FIT
|
3 months
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Investigatori
- Investigatore principale: Sarah Miller, PhD, RN, Medical University of South Carolina
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio (Stimato)
15 settembre 2026
Completamento primario (Stimato)
15 aprile 2030
Completamento dello studio (Stimato)
15 maggio 2031
Date di iscrizione allo studio
Primo inviato
21 agosto 2026
Primo inviato che soddisfa i criteri di controllo qualità
4 settembre 2026
Primo Inserito (Effettivo)
10 settembre 2026
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
15 settembre 2026
Ultimo aggiornamento inviato che soddisfa i criteri QC
10 settembre 2026
Ultimo verificato
1 settembre 2026
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- Pro00149990
- 1R01NR021347-01A1 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
SÌ
Descrizione del piano IPD
Study Protocol
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
No
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
No
prodotto fabbricato ed esportato dagli Stati Uniti
Sì
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .